Table S1 Number of biomarker measurements by time point and treatment arm Biomarker Baseline (VKA/rivaroxaban) End of treatment (VKA/rivaroxaban) D-dimer 901 (299/602) 882 (285/597) F1.2 950 (319/631) 909 (292/617) hs-CRP 950 (318/632) 905 (287/618) hs-IL-6 894 (298/596) 837 (268/569) TAT 931 (311/620) 895 (293/602) Total number of subjects 958 (320/638) 918 (294/624) Abbreviations: F1.2, prothrombin fragment 1þ2; hs-CRP, high-sensitivity C-reactive protein; hs-IL-6, high-sensitivity interleukin-6; TAT, thrombinanti-thrombin III complex; VKA, vitamin K antagonist.
Supplementary
hs-CRP À12.5% (95% CI: À19.9% to À4.4%; n ¼ 481) À17.9% (95% CI: À27.2% to À7.4%; n ¼ 259) 0.827 0.408 D-dimer À32.3% (95% CI: À36.2% to À28.2%; n ¼ 448) À37.7% (95% CI: À42.5% to À32.5%; n ¼ 245) 1.629 0.104 hs-IL-6 À9.2% (95% CI: À14.2% to À3.8%; n ¼ 417) À9.8% (95% CI: À16.6% to À2.5%; n ¼ 229) 0.144 0.886 F1.2 2.7% (95% CI: À5.6% to 11.7%; n ¼ 481) À53.0% (95% CI: À58.1% to À47.3%; n ¼ 264) 10.803 <0.001 TAT À28.0% (95% CI: À34.9% to À20.4%; n ¼ 462) À23.1% (95% CI: À32.8% to À12.0%; n ¼ 258) À0.763 0.446
Abbreviations: CI, confidence interval; F1.2, prothrombin fragment 1 þ 2; hs-CRP, high-sensitivity C-reactive protein; hs-IL-6, high-sensitivity interleukin-6; TAT, thrombin-anti-thrombin III complex; VKA, vitamin-K antagonist. a p-Values and t statistics are calculated from a linear model with the biomarker baseline level, treatment duration and treatment arm as independent variables. Consequently, the given mean changes are adjusted for treatment duration and biomarker baseline level.
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Supplementary À40.4 to À21.7%; n ¼ 250)
À29.9% (95% CI:
À41.8 to À15.7%; n ¼ 137)
À0.220
0.826
Type of AF ¼ long-standing persistent À43.2% (95% CI:
À70.4 to 8.7%; n ¼ 11)
17.0% (95% CI: À38.9 to 124.1%; n ¼ 11)
À1.546
0.123
Abbreviations: AF, atrial fibrillation; ANCOVA, analysis of covariance; CI, confidence interval; F1.2, prothrombin fragment 1þ2; HF, heart failure; hs-CRP, high-sensitivity C-reactive protein; hs-IL-6, high-sensitivity interleukin-6; OAC, oral anticoagulant; TAT, thrombin-anti-thrombin III complex; VKA, vitamin K antagonist. a p-Values were calculated from an ANCOVA that contained the biomarker baseline level, treatment duration and the treatment arm in addition to the respective factor variable. b p-Values and t-statistics were calculated from a linear model with the biomarker baseline level, treatment duration, treatment arm and the respective subgroup variable (as a main effect and in interaction with treatment) as independent variables. Consequently, the given mean changes are adjusted for treatment duration and biomarker baseline level.
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